JP2003526667A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2003526667A5 JP2003526667A5 JP2001566662A JP2001566662A JP2003526667A5 JP 2003526667 A5 JP2003526667 A5 JP 2003526667A5 JP 2001566662 A JP2001566662 A JP 2001566662A JP 2001566662 A JP2001566662 A JP 2001566662A JP 2003526667 A5 JP2003526667 A5 JP 2003526667A5
- Authority
- JP
- Japan
- Prior art keywords
- drug
- antiproliferative
- cephalotaxin
- use according
- agent
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000003814 drug Substances 0.000 description 21
- 230000001028 anti-proliverative effect Effects 0.000 description 14
- 229940079593 drug Drugs 0.000 description 14
- DSRNKUZOWRFQFO-UHFFFAOYSA-N cephalotaxine Natural products COC1=CC23CCCN2CCc4cc5OCOc5cc4C3=C1O DSRNKUZOWRFQFO-UHFFFAOYSA-N 0.000 description 13
- 239000003795 chemical substances by application Substances 0.000 description 9
- HYFHYPWGAURHIV-JFIAXGOJSA-N omacetaxine mepesuccinate Chemical compound C1=C2CCN3CCC[C@]43C=C(OC)[C@@H](OC(=O)[C@@](O)(CCCC(C)(C)O)CC(=O)OC)[C@H]4C2=CC2=C1OCO2 HYFHYPWGAURHIV-JFIAXGOJSA-N 0.000 description 6
- 206010028980 Neoplasm Diseases 0.000 description 3
- YMNCVRSYJBNGLD-KURKYZTESA-N cephalotaxine Chemical compound C([C@@]12C=C([C@H]([C@H]2C2=C3)O)OC)CCN1CCC2=CC1=C3OCO1 YMNCVRSYJBNGLD-KURKYZTESA-N 0.000 description 3
- HYFHYPWGAURHIV-UHFFFAOYSA-N homoharringtonine Natural products C1=C2CCN3CCCC43C=C(OC)C(OC(=O)C(O)(CCCC(C)(C)O)CC(=O)OC)C4C2=CC2=C1OCO2 HYFHYPWGAURHIV-UHFFFAOYSA-N 0.000 description 3
- 102000039446 nucleic acids Human genes 0.000 description 3
- 108020004707 nucleic acids Proteins 0.000 description 3
- 150000007523 nucleic acids Chemical class 0.000 description 3
- 229960002230 omacetaxine mepesuccinate Drugs 0.000 description 3
- 239000008194 pharmaceutical composition Substances 0.000 description 3
- UPALIKSFLSVKIS-UHFFFAOYSA-N 5-amino-2-[2-(dimethylamino)ethyl]benzo[de]isoquinoline-1,3-dione Chemical compound NC1=CC(C(N(CCN(C)C)C2=O)=O)=C3C2=CC=CC3=C1 UPALIKSFLSVKIS-UHFFFAOYSA-N 0.000 description 2
- KLWPJMFMVPTNCC-UHFFFAOYSA-N Camptothecin Natural products CCC1(O)C(=O)OCC2=C1C=C3C4Nc5ccccc5C=C4CN3C2=O KLWPJMFMVPTNCC-UHFFFAOYSA-N 0.000 description 2
- UHDGCWIWMRVCDJ-CCXZUQQUSA-N Cytarabine Chemical compound O=C1N=C(N)C=CN1[C@H]1[C@@H](O)[C@H](O)[C@@H](CO)O1 UHDGCWIWMRVCDJ-CCXZUQQUSA-N 0.000 description 2
- GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 description 2
- JXLYSJRDGCGARV-WWYNWVTFSA-N Vinblastine Natural products O=C(O[C@H]1[C@](O)(C(=O)OC)[C@@H]2N(C)c3c(cc(c(OC)c3)[C@]3(C(=O)OC)c4[nH]c5c(c4CCN4C[C@](O)(CC)C[C@H](C3)C4)cccc5)[C@@]32[C@H]2[C@@]1(CC)C=CCN2CC3)C JXLYSJRDGCGARV-WWYNWVTFSA-N 0.000 description 2
- 229960004701 amonafide Drugs 0.000 description 2
- VSJKWCGYPAHWDS-FQEVSTJZSA-N camptothecin Chemical compound C1=CC=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)[C@]5(O)CC)C4=NC2=C1 VSJKWCGYPAHWDS-FQEVSTJZSA-N 0.000 description 2
- 229940127093 camptothecin Drugs 0.000 description 2
- DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 description 2
- 229960004316 cisplatin Drugs 0.000 description 2
- -1 cortisin Chemical compound 0.000 description 2
- 229960000684 cytarabine Drugs 0.000 description 2
- VSJKWCGYPAHWDS-UHFFFAOYSA-N dl-camptothecin Natural products C1=CC=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)C5(O)CC)C4=NC2=C1 VSJKWCGYPAHWDS-UHFFFAOYSA-N 0.000 description 2
- 229960005420 etoposide Drugs 0.000 description 2
- VJJPUSNTGOMMGY-MRVIYFEKSA-N etoposide Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@H](C)OC[C@H]4O3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 VJJPUSNTGOMMGY-MRVIYFEKSA-N 0.000 description 2
- 229960002949 fluorouracil Drugs 0.000 description 2
- 229940045109 genistein Drugs 0.000 description 2
- TZBJGXHYKVUXJN-UHFFFAOYSA-N genistein Natural products C1=CC(O)=CC=C1C1=COC2=CC(O)=CC(O)=C2C1=O TZBJGXHYKVUXJN-UHFFFAOYSA-N 0.000 description 2
- 235000006539 genistein Nutrition 0.000 description 2
- ZCOLJUOHXJRHDI-CMWLGVBASA-N genistein 7-O-beta-D-glucoside Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=CC(O)=C2C(=O)C(C=3C=CC(O)=CC=3)=COC2=C1 ZCOLJUOHXJRHDI-CMWLGVBASA-N 0.000 description 2
- 239000003112 inhibitor Substances 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 229960003048 vinblastine Drugs 0.000 description 2
- JXLYSJRDGCGARV-XQKSVPLYSA-N vincaleukoblastine Chemical compound C([C@@H](C[C@]1(C(=O)OC)C=2C(=CC3=C([C@]45[C@H]([C@@]([C@H](OC(C)=O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(=O)OC)N3C)C=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1NC1=CC=CC=C21 JXLYSJRDGCGARV-XQKSVPLYSA-N 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 229940100198 alkylating agent Drugs 0.000 description 1
- 239000002168 alkylating agent Substances 0.000 description 1
- 150000004696 coordination complex Chemical class 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 239000000138 intercalating agent Substances 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- MRWXACSTFXYYMV-FDDDBJFASA-N nebularine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C2=NC=NC=C2N=C1 MRWXACSTFXYYMV-FDDDBJFASA-N 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 239000002212 purine nucleoside Substances 0.000 description 1
- 239000002718 pyrimidine nucleoside Substances 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 230000004614 tumor growth Effects 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US18969900P | 2000-03-15 | 2000-03-15 | |
| US60/189,699 | 2000-03-15 | ||
| PCT/US2001/008480 WO2001068098A2 (en) | 2000-03-15 | 2001-03-15 | Cephalotaxine alkaloid combination compositions and uses thereof |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2003526667A JP2003526667A (ja) | 2003-09-09 |
| JP2003526667A5 true JP2003526667A5 (enExample) | 2008-05-08 |
| JP4929436B2 JP4929436B2 (ja) | 2012-05-09 |
Family
ID=22698410
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2001566662A Expired - Fee Related JP4929436B2 (ja) | 2000-03-15 | 2001-03-15 | セファロタキシンアルカロイド組成物およびその使用 |
Country Status (11)
| Country | Link |
|---|---|
| US (4) | US6734178B2 (enExample) |
| EP (1) | EP1263440B1 (enExample) |
| JP (1) | JP4929436B2 (enExample) |
| AT (1) | ATE330611T1 (enExample) |
| AU (2) | AU4580301A (enExample) |
| CA (1) | CA2402710A1 (enExample) |
| DE (1) | DE60120928T2 (enExample) |
| DK (1) | DK1263440T3 (enExample) |
| ES (1) | ES2267741T3 (enExample) |
| PT (1) | PT1263440E (enExample) |
| WO (1) | WO2001068098A2 (enExample) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2402710A1 (en) * | 2000-03-15 | 2001-09-20 | Chemgenex Therapeutics, Inc. | Use of a cephalotaxine and an antiproliferative agent in treating cellular proliferative disease |
| ATE305312T1 (de) * | 2000-04-12 | 2005-10-15 | Chemgenex Pharmaceuticals Inc | Zusammensetzungen welche ein naphthalmid und ein antiproliferatives mittel enthalten |
| US20060211648A1 (en) * | 2000-04-12 | 2006-09-21 | Chemgenex Pharmaceuticals, Inc. | Naphthalimide compositions and uses thereof |
| US7135481B2 (en) | 2000-04-12 | 2006-11-14 | Chemgenex Pharmaceuticals, Inc. | Naphthalimide compositions and uses thereof |
| US20050170015A1 (en) * | 2000-10-31 | 2005-08-04 | Brown Dennis M. | Antiproliferative colchicine compositions and uses thereof |
| US20020123469A1 (en) * | 2000-10-31 | 2002-09-05 | Brown Dennis M. | Antiproliferative colchicine compositions and uses thereof |
| DE60313754T2 (de) * | 2002-03-06 | 2008-01-24 | The Medical Research and Education Trust, San Diego | Botanischer extrakt mit antikrebs-aktivität enthaltend isoliquiritigenin |
| AU2003253872A1 (en) * | 2002-07-17 | 2004-02-09 | Chemgenex Pharmaceuticals, Inc. | Formulations and methods of administration of cephalotaxines, including homoharringtonine |
| ES2572145T3 (es) * | 2002-07-22 | 2016-05-30 | Teva Pharmaceuticals Int Gmbh | Inhibición de la angiogénesis mediante alcaloides de cefalotoxina, derivados, composiciones y usos de los mismos |
| CN100396286C (zh) * | 2002-12-30 | 2008-06-25 | 北京大学第一医院 | 高三尖杉酯碱和三尖杉酯碱在制备抑制血管生成药物中的应用 |
| US20050288310A1 (en) * | 2004-06-04 | 2005-12-29 | Chemgenex Pharmaceuticals, Inc. | Methods of treating cellular proliferative disease using naphthalimide and PARP-1 inhibitors |
| US20060193893A1 (en) * | 2005-02-10 | 2006-08-31 | Chemgenex Pharmaceuticals, Inc. | Medical devices |
| WO2008128191A2 (en) * | 2007-04-13 | 2008-10-23 | Chemgenex Pharmaceuticals, Inc. | Oral cephalotaxine dosage forms |
| EP2260041A4 (en) | 2008-03-03 | 2012-04-25 | Sloan Kettering Inst Cancer | CEPHALOTAXUS ESTERS, METHOD FOR THEIR SYNTHESIS AND USES THEREOF |
| CN118217301B (zh) * | 2024-03-28 | 2025-08-05 | 宁波大学附属人民医院 | 一种协同治疗aml的含有8-氯腺苷和高三尖杉酯碱的药物组合物 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4399282A (en) * | 1979-07-10 | 1983-08-16 | Kabushiki Kaisha Yakult Honsha | Camptothecin derivatives |
| US4675318A (en) * | 1985-05-28 | 1987-06-23 | Yaguang Liu | Safe antileukemia drug, SAL |
| US5391745A (en) * | 1992-07-23 | 1995-02-21 | Sloan-Kettering Institute For Cancer Research | Methods of preparation of camptothecin analogs |
| CA2402710A1 (en) * | 2000-03-15 | 2001-09-20 | Chemgenex Therapeutics, Inc. | Use of a cephalotaxine and an antiproliferative agent in treating cellular proliferative disease |
| ATE305312T1 (de) * | 2000-04-12 | 2005-10-15 | Chemgenex Pharmaceuticals Inc | Zusammensetzungen welche ein naphthalmid und ein antiproliferatives mittel enthalten |
-
2001
- 2001-03-15 CA CA002402710A patent/CA2402710A1/en not_active Abandoned
- 2001-03-15 AU AU4580301A patent/AU4580301A/xx active Pending
- 2001-03-15 DK DK01918763T patent/DK1263440T3/da active
- 2001-03-15 DE DE60120928T patent/DE60120928T2/de not_active Expired - Lifetime
- 2001-03-15 AU AU2001245803A patent/AU2001245803B8/en not_active Ceased
- 2001-03-15 AT AT01918763T patent/ATE330611T1/de active
- 2001-03-15 US US09/810,527 patent/US6734178B2/en not_active Expired - Lifetime
- 2001-03-15 PT PT01918763T patent/PT1263440E/pt unknown
- 2001-03-15 ES ES01918763T patent/ES2267741T3/es not_active Expired - Lifetime
- 2001-03-15 EP EP01918763A patent/EP1263440B1/en not_active Expired - Lifetime
- 2001-03-15 WO PCT/US2001/008480 patent/WO2001068098A2/en not_active Ceased
- 2001-03-15 JP JP2001566662A patent/JP4929436B2/ja not_active Expired - Fee Related
-
2004
- 2004-01-30 US US10/769,638 patent/US20040185117A1/en not_active Abandoned
-
2010
- 2010-04-15 US US12/761,251 patent/US20110008307A1/en not_active Abandoned
-
2011
- 2011-12-23 US US13/336,917 patent/US20120207855A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2003526667A5 (enExample) | ||
| CA2446435A1 (en) | 4-amino-5-phenyl-7-cyclobutyl-pyrrolo[2,3-d]pyrimidine derivatives | |
| JP2003530431A5 (enExample) | ||
| WO2004002422A3 (en) | 2’-c-methyl-3’-o-l-valine ester ribofuranosyl cytidine for treatment of flaviviridae infections | |
| CA2512475A1 (en) | Compositions and methods for combination antiviral therapy | |
| EP2330194A3 (en) | Non-sequence complementary antiviral oligonucleotides | |
| IL168266A (en) | Nucleoside derivatives, processes for their preparation. pharmaceutical compositions comprising them and uses thereof for the manufacture of medicaments | |
| RU2011139180A (ru) | Комбинация нуклеозидного ингибитора полимеразы и макроциклического ингибитора протеазы и ее применение для лечения гепатита с, фиброза печени и нарушенной печеночной функции | |
| JP2004500390A5 (enExample) | ||
| JP2006504745A5 (enExample) | ||
| US20130184232A1 (en) | Methods for administering dpd inhibitors in combination with 5-fu and 5-fu prodrugs | |
| IN2012DN06436A (enExample) | ||
| WO2009026292A1 (en) | Dosing methods for treating disease | |
| WO2001062235A3 (en) | A composition comprising camptothecin and a pyrimidine derivative for the treatment of cancer | |
| IL175568A (en) | Tyrosine kinase inhibitors, containing them containing herbal remedies and their use in the preparation of a drug for the treatment of diseases | |
| EE200300429A (et) | Tegafuri, uratsiili, foliinhappe, paklitakseeli ja karboplatiini kasutamine ravimkoostise valmistamiseks kasvaja raviks | |
| JP2003534286A5 (enExample) | ||
| CA2404278A1 (en) | Naphthalimide compositions and uses thereof | |
| IL164973A (en) | N-hydroxy formamide compounds, pharmaceutical compositions comprising them and use thereof in the preparation of medicaments for treating bacterial infections | |
| JP2003514025A5 (enExample) | ||
| CA2518195A1 (en) | Antitumor effect potentiator and antitumor agent | |
| WO2007064448A3 (en) | Cancer treatment using fts and 2-deoxyglucose | |
| JP2016014051A (ja) | ５−ｆｕ又はそのプロドラッグと、ｄｐｄ阻害剤との組合せに付随した神経毒性の処置 | |
| JP2004502785A5 (enExample) | ||
| WO2005023270A3 (en) | Compositions and methods for use of antiviral drugs in the treatment of retroviral diseases resistant to nucleoside reverse transcriptase inhibitors |